Loading...
Market
Will Zevra's drug Miplyffa reach $100 million in sales by the end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Zevra Therapeutics' official financial reports
Story
FDA Approves Zevra's Oral Drug Miplyffa for Niemann-Pick Disease Type C
Sep 20, 2024, 05:11 PM
The U.S. Food and Drug Administration (FDA) has approved Zevra Therapeutics' drug, Miplyffa, as the first oral medication to treat Niemann-Pick disease, type C (NPC). This approval, announced on September 20, 2024, marks a significant milestone for the treatment of this rare and fatal genetic disorder, which affects neurons. Parents and advocates have pushed for years for treatments for NPC, facing numerous setbacks before achieving this breakthrough.
View original story
Similar markets
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%